Skip to main content

Corporate insider profile

Gary K. Lee Insider Trades

Gary K. Lee has reported no open-market purchases on SEC Form 4 and is a net seller of $29,035 across 1 company. The most recent open-market transaction was reported on Nov 10, 2026. Source: SEC Form 4 filings.

Latest reported as Chief Scientific Officer of Lyell Immunopharma, Inc. (LYEL).

SEC-reported filing activity is provided for research purposes and is not investment advice.

Purchase filings
0
Reported companies
1
Net open-market value
-$29,034.89
Latest transaction
Nov 10, 2026

Affiliated corporations

Reported company relationships

Transaction history

Open-market Transactions

Open-market insider purchase and sale transactions
DateCompanyRoleTypeSharesPriceTotal value
Nov 10, 2026Lyell Immunopharma, Inc. (LYEL)Chief Scientific OfficerSale129$15.93$2,055
Aug 21, 2026Lyell Immunopharma, Inc. (LYEL)Chief Scientific OfficerSale1,457$15.54$22,642
Aug 10, 2026Lyell Immunopharma, Inc. (LYEL)Chief Scientific OfficerSale131$14.34$1,879
May 11, 2026Lyell Immunopharma, Inc. (LYEL)Chief Scientific OfficerSale130$18.92$2,460

Common questions

Gary K. Lee insider trading FAQ

Is Gary K. Lee buying or selling stock?
Across all SEC Form 4 open-market filings on record, Gary K. Lee is a net seller of $29,035, with no open-market purchases reported. The latest transaction was reported on Nov 10, 2026.
Which companies does Gary K. Lee report insider trades for?
Gary K. Lee has reported open-market trades in Lyell Immunopharma, Inc. (LYEL). The latest SEC-reported relationship is Chief Scientific Officer of Lyell Immunopharma, Inc. (LYEL).
Where does Gary K. Lee's insider trading data come from?
Watch Insiders reads the SEC Form 4 filings submitted to EDGAR under reporting owner CIK 1907345, and refreshes this page daily.